Literature DB >> 3341510

Mammary duct ectasia and pituitary adenomas.

S Shousha1, C M Backhouse, P M Dawson, J Alaghband-Zadeh, I Burn.   

Abstract

Mammary duct ectasia developed in three postmenopausal patients who had had pituitary chromophobe adenomas. The first patient had bilateral duct ectasia that developed 8 and 11 years after hypophysectomy. The second patient, who also had bilateral ectasia, had a prolactin-producing pituitary adenoma for which bromocriptine was prescribed. The ectasia developed in one breast before commencing bromocriptine therapy, and in the other breast 2 years later. The third patient also had a prolactin-producing pituitary adenoma. Unilateral duct ectasia developed while bromocriptine was taken. The ectasia in all patients was very marked and affected all excised ducts. Cholesterol granulomas were sometimes very extensive. These cases suggest a relationship between certain hypothalamic/pituitary disorders, possibly related to prolactin secretion and the development of mammary duct ectasia in postmenopausal patients.

Entities:  

Mesh:

Year:  1988        PMID: 3341510     DOI: 10.1097/00000478-198802000-00006

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  3 in total

Review 1.  A rare case of male breast ductal carcinoma in-situ associated with prolactinoma.

Authors:  Chandike Maithri Mallawaarachchi; Snezana Ivanova; Alice Shorthouse; Sami Shousha; Dudley Sinnett
Journal:  BMJ Case Rep       Date:  2011-08-31

2.  Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study.

Authors:  S Gill; D Peston; B K Vonderhaar; S Shousha
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

3.  Bilateral mammary duct ectasia induced by sulpiride-associated hyperprolactinemia: A case report.

Authors:  Yizi Cong; Haidong Zou; Guangdong Qiao; Jun Lin; Xingmiao Wang; Xiaohui Li; Yalun Li; Shiguang Zhu
Journal:  Oncol Lett       Date:  2015-03-12       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.